search
Back to results

Intraoperative Fluorescence Angiography in Debridement of Open Fractures

Primary Purpose

Intraoperative Fluorescence Angiography

Status
Not yet recruiting
Phase
Not Applicable
Locations
United States
Study Type
Interventional
Intervention
Intraoperative fluorescence angiography
Sponsored by
Vanderbilt University Medical Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Intraoperative Fluorescence Angiography

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  • All adults ≥18 years old
  • Open type II or type III upper or lower extremity fracture to be treated at Vanderbilt University Medical Center with operative intervention by orthopaedic trauma or orthopaedic hand surgeons.

Exclusion Criteria:

  • Patients <18 years old
  • Pregnant
  • In extremis or requiring expedited surgical care outside of standard treatment
  • Allergy or medical contraindication to indocyanine green dye.

Sites / Locations

  • Vanderbilt Orthopaedics

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Intraoperative fluorescence angiography

Arm Description

Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.

Outcomes

Primary Outcome Measures

Additional debridement following IFA use
Yes/No

Secondary Outcome Measures

Full Information

First Posted
August 7, 2021
Last Updated
August 20, 2023
Sponsor
Vanderbilt University Medical Center
search

1. Study Identification

Unique Protocol Identification Number
NCT05006313
Brief Title
Intraoperative Fluorescence Angiography in Debridement of Open Fractures
Official Title
Intraoperative Fluorescence Angiography in Debridement of Open Fractures
Study Type
Interventional

2. Study Status

Record Verification Date
August 2023
Overall Recruitment Status
Not yet recruiting
Study Start Date
July 1, 2024 (Anticipated)
Primary Completion Date
October 31, 2024 (Anticipated)
Study Completion Date
October 31, 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Vanderbilt University Medical Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
Yes
Product Manufactured in and Exported from the U.S.
Yes
Data Monitoring Committee
No

5. Study Description

Brief Summary
The proposed research aims to be a pilot feasibility study to evaluate intraoperative fluorescence angiography (IFA) as an aid for acute debridement in orthopaedic trauma.
Detailed Description
The investigators will perform a prospective cohort study evaluating the utility of IFA in acute debridement of type II and type III open extremity fractures by testing the frequency that IFA leads to additional debridement of compromised tissue. The investigators will also identify the incidence of clinically important secondary outcomes for future evaluation in a multicenter randomized controlled trial. Secondary outcomes will include the occurrence of a secondary procedure for surgical debridement, the need for a soft tissue coverage procedure, and the incidence of post-operative wound complications. Additionally, the investigators will evaluate surgeon experience using IFA to understand ease of use and surgeon satisfaction. At the conclusion of this study, the investigators will be able to understand how often IFA may assist surgeons perform successful debridement and potential advantages of use. IFA may improve debridement by identifying tissue that is not viable but difficult to assess by the current gold standard, clinical acumen, or by giving surgeons confidence that the debridement is adequate and that the wound may be safely closed. Ultimately, IFA may prove to reduce the need for further procedures and potentially reduce the post-operative infection rate. Aim 1: Evaluate the frequency that IFA leads to the debridement of additional tissue during the same operative procedure for type II and type III open extremity fractures following an initial debridement using clinical measures of tissue viability. Hypothesis: Adult patients (≥18 years old) undergoing surgical debridement of an upper or lower extremity type II or type III open fracture will have additional tissue debrided after use of IFA in at least 18% of cases, the frequency reported in plastic surgery literature. A) Patients will undergo a standard initial debridement by the treating surgeon. When the surgeon feels the debridement is complete, IFA will be performed. B) The amount and type of additional tissue debrided will be recorded. Percent perfusion on IFA imaging will be recorded for all tissue that requires additional debridement compared with a pre-selected reference. Aim 2: Evaluate incidence of post-operative wound complications, repeat debridement, or soft tissue coverage after debridement is performed using IFA for type II and type III open extremity fractures. Hypothesis: Adult patients (≥18 years old) undergoing surgical debridement of an upper or lower extremity type II or type III open fracture with the use of IFA will have a lower post-operative infection or dehiscence rate and require fewer procedures for repeat debridement or coverage compared to institutional standards. A) Patients will undergo a standard initial debridement by the treating surgeon. When the surgeon feels the debridement is complete, IFA will be performed. B) Post-operative surgical site infection requiring debridement or antibiotic treatment or wound dehiscence requiring wound care or surgery will be noted within 30-days from the initial debridement. C) The occurrence and number of repeat debridement procedures will be noted until definitive wound closure or reconstruction. The need for soft tissue coverage and type of coverage will be noted for each injury. Aim 3: Evaluate surgeon experience using IFA for acute debridement of type II and type III open extremity fractures. Hypothesis: Surgeons rate the use of IFA as easy and helpful. A) Patients will undergo a standard initial debridement by the treating surgeon. When the surgeon feels the debridement is complete, IFA will be performed. B) After surgery, surgeons will complete a surgeon assessment form assessing ease of use, if the surgeon felt IFA to be helpful, and overall satisfaction based on a Likert-type scale.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Intraoperative Fluorescence Angiography

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
20 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Intraoperative fluorescence angiography
Arm Type
Experimental
Arm Description
Intraoperative fluorescence angiography will be utilized to view initial debridement area. Using a sterile marking pen, the surgeon will mark the areas of tissue on skin, subcutaneous tissue, muscle, bone, or other that he or she wishes to debride further due to poor perfusion. A reference point on uninjured tissue of the same extremity at least 10 cm from the wound will be identified and measured for perfusion (set to reference of 100% perfusion). The area to be further debrided will be measured for percent perfusion relative to this reference point.
Intervention Type
Device
Intervention Name(s)
Intraoperative fluorescence angiography
Intervention Description
Intraoperative fluorescence angiography will be used to assess tissue perfusion following initial debridement of wound.
Primary Outcome Measure Information:
Title
Additional debridement following IFA use
Description
Yes/No
Time Frame
Intraoperative

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: All adults ≥18 years old Open type II or type III upper or lower extremity fracture to be treated at Vanderbilt University Medical Center with operative intervention by orthopaedic trauma or orthopaedic hand surgeons. Exclusion Criteria: Patients <18 years old Pregnant In extremis or requiring expedited surgical care outside of standard treatment Allergy or medical contraindication to indocyanine green dye.
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
Julie M Shelton, BBA
Phone
6153224506
Email
Julie.M.Daniels@vumc.org
First Name & Middle Initial & Last Name or Official Title & Degree
Jed I Maslow, MD
Phone
615-322-4683
Email
Jed.I.Maslow@vumc.org
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Jed I Maslow, MD
Organizational Affiliation
Vanderbilt University Medical Center
Official's Role
Principal Investigator
Facility Information:
Facility Name
Vanderbilt Orthopaedics
City
Nashville
State/Province
Tennessee
ZIP/Postal Code
37232
Country
United States

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Intraoperative Fluorescence Angiography in Debridement of Open Fractures

We'll reach out to this number within 24 hrs